Accurate determination of radionuclide purity and half-life of reactor produced LU-177G for metabolic radioimmunotherapy

F. Groppi, L. Canella, M. L. Bonardi, C. Zona, S. Morzenti, E. Menapace, Z. B. Alfassi, M. Chinol, S. Papi, G. Tosi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The accurate determination of radionuclidic purity and half-life of the beta emitter 177gLu used for metabolic radioimmunotherapy is presented. High-resolution gamma spectrometry, as well as deconvolution of beta decay curve measured by spectrometry with liquid scintillation counting, have been adopted for quality control of different samples available on the market. A simple method was developed to distinguish between the different methods available for production of 177gLu: i.e. either direct (n,y) reactions of enriched 176Lu or indirect (n,y) activation of enriched 176Yb followed by P" decay. In the first case, the long-lived metastable level 177mLu is present in the radioactive preparation and a low specific activity radionuclide is obtained, in the latter a very high purity and high specific activity 177gLu is produced.

Original languageEnglish
Title of host publicationAstroparticle, Particle and Space Physics, Detectors and Medical Physics Applications - Proceedings of the 9th Conference
Pages710-714
Number of pages5
Publication statusPublished - 2006
EventInternational Conference on Advanced Technology and Particle Physics, ICATPP 2005 - Como, Italy
Duration: Oct 17 2005Oct 21 2005

Other

OtherInternational Conference on Advanced Technology and Particle Physics, ICATPP 2005
CountryItaly
CityComo
Period10/17/0510/21/05

ASJC Scopus subject areas

  • Astronomy and Astrophysics
  • Nuclear and High Energy Physics

Fingerprint Dive into the research topics of 'Accurate determination of radionuclide purity and half-life of reactor produced LU-177G for metabolic radioimmunotherapy'. Together they form a unique fingerprint.

Cite this